Company intelligence / Profile preview

GlycoNex

New Taipei City, Taiwanglyconex.com.tw ↗

Ownership: Public · 4168
Development stage: Preclinical

Overview

GlycoNex has completed Phase 1 trials for its lead monoclonal antibody GNX102 with excellent safety and promising efficacy. Its ADC candidate GNX1021 has shown potent tumor inhibition in preclinical gastric cancer models and is advancing toward IND-enabling studies. The company also has a denosumab biosimilar in Phase 3 clinical trials.

Therapeutic areas: OphthalmologyOncologyEndocrinology
Modalities: Monoclonal antibodyAntibody-drug conjugateRecombinant fusion proteinSmall molecule
Industry: Biotech

Drug pipeline

9 assets

GNX102

8 more assets in the full pipeline.

Request access →

Partnerships

PrecisemAb (technology licensing agreement for Universal Antibody Lock)

Beyond the preview

Go deeper on GlycoNex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoNex.

Explore the full profile